OUHSC Research News – Monday, January 16, 2023

 

Notices and Reminders

Important ORA Notice: All grant and contract proposals MUST be submitted to ORA (through SoonerTrack) for review, approval, and submission, regardless of the type of grant or contract, whether it is for research, public outreach initiatives, professional or public services, or whether it involves payment. This includes contracts with OU Health.

Please note that all certifications, contracts, agreements, and other award acceptance documents must be signed by an ORA Authorized Official. Faculty and staff are NOT authorized to sign grants or contracts on behalf of the University or on behalf of any University department or employee. Only the ORA’s Authorized Official may accept a grant award or negotiate and execute contract details on behalf of the University.

 

Reminder of Upcoming New NIH Data Management and Sharing Policy Requirements

The National Institute of Health (NIH) has implemented a new Policy for Data Management and Sharing (DMS Policy), which will take effect January 25, 2023. The policy requires ALL new and competing proposals/renewals that will generate scientific data to submit a detailed plan outlining how data will be stored, protected, and ultimately shared. Below you can find some guidance and resources for creating a DMS Plan.

• For applications being developed for due dates on or after January 25, 2023, a DMS Plan (recommended to be two pages or less in length) should be attached unless not required by the Funding Opportunity Announcement (FOA) or Forms H Guidelines. Please note that a Resource Sharing Plan should still be included for sharing model organisms.
• If data management and sharing costs are budgeted in a detailed budget, this should be described in the budget justification. Data management and sharing costs should be categorized under “Other Direct costs” on their own line.
• If it is a modular budget and data management and sharing costs are planned, the “Additional Narrative” attachment should be included.
• Do not include hypertext (e.g., hyperlinks and URLs) in the DMS Plan attachment.
• NIH Resources: Check out the latest DMS policy information, resources, format page, and FAQs at sharing.nih.gov.
• ORA Webinar: Understanding the New NIH Data Management and Sharing (DMS) Policy (October. 26, 2022). To access the training, please click here

 

Workshops and Seminars

Navigating the World of Sponsored Research: An Overview

Offered jointly by the Office of Research Administration (ORA) and Grants & Contracts Accounting Office (GCA)

Date: January 26, 2023

Time: 8:00 am– 12:00 pm and 1:00 pm - 4:00 pm

Venue: Presbyterian Health Foundation (PHF) Conference Center, University Research Park, Building 655, Suite 100, Oklahoma City

Tulsa: Schusterman Learning Center, Rooms 138 & 231

 

Ever needed help with a grant submission?

Are budget questions keeping you from your real job?

Not quite sure how to support your faculty with their grants and contracts?

Finally, the moment you’ve been waiting for….

We are pleased to announce a joint workshop, “Navigating the World of Sponsored Research: An Overview” for faculty and staff.  This workshop will offer a one-day training on sponsored research topics. 

Registration is required and can be done by completing the following form: https://ousurvey.qualtrics.com/jfe/form/SV_88NVoGwcHTrpmNU

The deadline to register for the workshop is Friday, January 20, 2023.

If you have any questions, please contact Sogol Rasouli at sogol-rasouli@ouhsc.edu.

Additional information: Please refer to the attached agenda.

 

2023 Annual Cancer Research Symposium

Registration and Abstract Submission Open Now!

The Annual Cancer Research Symposium is a one-day event with research focused in cancer biology, cancer prevention and control, and cancer therapeutics. The target audience is faculty, staff, postdoctoral and graduate students, and other cancer research focused colleagues. 
WHEN Friday, March 10, 9:30 am - 5:10 pm (Reception to follow)
WHERE Nicholson Tower - 1000 NE 13th St. OKC, OK 73104
REGISTER Register HERE.
CALL FOR ABSTRACT Abstracts are due by Friday, January 20 at 5pm. Abstract guidelines can be located HERE. Please submit abstracts HERE.
Questions? If you have any questions regarding the symposium, please contact Emily Hulseberg at Emily-Hulseberg@ouhsc.edu.

 

OUHSC Funding Opportunities

OUHSC College of Medicine Research Fund

Description: Proposals are being accepted from full time faculty of the College of Medicine for grants to be awarded from the College of Medicine Alumni Association with proceeds generated from the Evening of Excellence dinner fund.  COMAA awards are intended to be an important resource for funding basic and clinical research projects of new and early stage investigators in the College of Medicine. The guidelines are included with this notice. Applications will be reviewed by a scientific panel whose composition will be determined on the types of applications received.  Awards generally fall within the $20,000 to $45,000 range ($45,000 maximum request). 

All applications must be routed through the Office of Research Administration and include the NIH face page (https://grants.nih.gov/grants/funding/phs398/fp1.pdf) signed by the appropriate ORA institutional official.

Below are New Guidelines for routing applications and for formatting applications for the COLLEGE OF MEDICINE ALUMNI ASSOCIATION (COMAA) research program:

1. Submission of application for review

1. At least five days prior to submission of the grant application, you must submit an electronic routing form using SOONERTRACKGRANTS (http://soonertrack.ouhsc.edu/SoonerTrackGrants.aspx). 
2. This program follows a Just-In-Time application process; therefore, approval of Institutional Review Board, Institutional Animal Care and Use Committee, Radiation Safety Committee and Institutional Biosafety Committee, where applicable, are not needed unless the application is being recommended for COMAA funding.  Applicants should only submit this information when it is requested by the Office of the Vice President for Research.  All protocols must be approved by the relevant review committees before funds are awarded.
3. The completed COMAA application must be submitted via e-mail to COMAA-Research@ouhsc.edu (cc marybeth-humphrey@ouhsc.edu) no later than 5 pm, Wednesday, April 5, 2023.  The application must be a single file in a pdf format and be titled “COMAA_[PI Name]”.  Only applications that conform to the COMAA Grant Guidelines will be forwarded to the Grant Review Panel for consideration.
4. Questions about the application submission process should be addressed to Associate Dean for Research for the College of Medicine, Dr. Mary Beth Humphrey (Marybeth-humphrey@ouhsc.edu).

Please submit an electronic copy of the application along with a copy of the Completed and Approved Soonertrack Routing Form (Soonertrackgrants.ouhsc.edu).  A screenshot of the completed online PDF form will be accepted). Application must be reviewed and approved for submission by the Office of Research Administration (ORA) prior to the final application being submitted. 

The start date for funded COMAA proposals will be July 1, 2023.

Applications Due: Applications should be sent electronically to COMAA-Research@ouhsc.edu by 5 pm on Wednesday, April 5, 2023. 

Guidelines for the Submission of Proposals: Please refer to the attached application guide.

 

The Oklahoma Center for Microbial Pathogenesis and Immunity, Phase 1 CoBRE Research Project Funding Opportunity

The Oklahoma Center for Microbial Pathogenesis and Immunity (OCMP&I) Phase 1 CoBRE is seeking candidates to become research project leaders (RPLs). The OCMP&I CoBRE expects to support new RPLs during years 4 and 5 of this Phase 1 program, with the possibility of extending projects into Phase 2 of the program. 

Research topics appropriate for the OCMP&I CoBRE include physiology and genetics of microbial pathogens, virulence factor mechanism of action, microbiome, zoonotic transmission, antimicrobials, and emerging pathogens. Relevant topics in immunology include, host responses to infection, innate and adaptive immunity, inflammation, autoimmunity, and immunogenetics.

Funding:  Funding levels will be determined based on the justifiable needs of the project, which have ranged from $150,000 to $200,000 annual direct costs for previous grants in this program.  

Eligibility: Applicants should hold an unmodified academic title, preferably at the Assistant Professor level. In accordance with NIH CoBRE guidelines an eligible RPL is “1) an individual who does not have and has not previously had an external, peer-reviewed RPG or Program Project Grant (PPG) from either a Federal or non-Federal source that names that investigator as the PD/PI or (2) an established investigator who is making a significant change to his/her career.”   Eligible RPLs cannot have received significant support through NIH R01, K99/R00, or P01, NSF, or other Federal or non-Federal agency awards. R03, R15, K01 and K08 awardees are eligible to be RPLs in this program. Research project leaders must commit 50% (6 calendar months) effort to their project. 

Application Process:  Interested candidates should submit 1) a two-page application that summarizes the specific aims of their research and future directions, 2) An NIH Biosketch. Applications should be emailed to jimmy-ballard@ouhsc.edu. Review of applications will begin January 27^th, 2023. 

Contact: Jimmy Ballard, PhD, OCMP&I CoBRE PI, Department of Microbiology and Immunology Office Phone:  405-271-2133, x46608; jimmy-ballard@ouhsc.edu

 

Call for Applications: PHF Equipment, Symposium, and Seed Grant Programs

Grant Type	Deadline
Research Support	February 24, 2023
New Investigator Seed (requires nomination by college)	March 10, 2023
Clinician Scientist Development	March 10, 2023
Team Science	March 24, 2023

 

 

 

 

 

 

 

 

 

 

Presbyterian Health Foundation (PHF) Research Support Grant Program – Request For Applications

• Cycle I PHF Research Support Grant Program Deadline: February 24, 2023

The PHF Research Support Grant Program will help support senior doctoral graduate students working on an externally funded research project in order to accelerate progress on the project, increase the number of publications on the project, and position the project for continued external funding. Outcomes of this program will be based upon work performed by the graduate student resulting in publications and external funding and will be carefully recorded and tracked.

The Principal Investigator must be an OUHSC primary faculty member. Principal Investigators who are full-time OUHSC faculty members, have external funds that support the project a senior graduate student is working on, and are the research mentor of the senior doctoral graduate student are eligible to apply.

Graduate students being supported by the PHF Research Support Grant program must be doctoral graduate students, have finished the majority of their coursework, and have a dissertation research project that is supporting an externally funded research project. The PHF funds must only fund that part of the stipend where the student is working on the externally funded research project. The Principal Investigator must have the funds to support the externally funded research project that the graduate student is working on and is expected to have funds to cover the rest of the graduate student’s stipend and other costs related to the graduate student’s education. Second year and third year funding is dependent upon meeting milestones proposed in prior year grant proposal. There are no restrictions on holding other PHF Grants during the duration of this award.  A Principal Investigator may not hold more than two PHF Research Support Grants concurrently.

 

Presbyterian Health Foundation (PHF) New Investigator Seed Grant Program – Request For Applications

• Cycle I PHF New Investigator Seed Grant Program Deadline: March 10, 2023

The primary objective of the PHF New Investigator Seed Grant Program is to provide a two-year grant for OUHSC New Investigators to initiate research programs and obtain extramural funding. A secondary objective is to fund highly promising New Investigators from each of the six OUHSC professional colleges. Applicants must fit the following definition of a New Investigator: An investigator who has not previously received substantial, independent funding from NIH (e.g. R01-type funding) or a comparable funding agency.  Multi-PI applications are not allowed. Each of the six OUHSC professional colleges (Allied Health, Dentistry, Medicine, Nursing, Pharmacy, and Public Health) may nominate one faculty member for this award. Applicants must be nominated by their professional college in order to apply for this award. The professional college nominating the faculty member must agree to assign a mentor for this project and must commit to providing the mentor with $2,500/year for mentoring activities; the mentor does not need to be an OUHSC faculty member. Each college may set up their own nomination process for this award.

The Principal Investigator must be an OUHSC primary faculty member. Principal Investigators with Temporary Faculty appointments (faculty with academic titles such as instructor, lecturer, or titles modified by prefixes such as visiting, adjunct, clinical, or temporary research appointments with suffix “of Research”) must obtain approval from the Vice President for Research before submitting an application for this program. Approval will require a letter from their Department Chairperson indicating a departmental commitment of salary, research space, and time for development of an independent career at OUHSC. Requests should be sent to ORA4PHF@ouhsc.edu

PHF New Investigator Seed Grant recipients may not hold a PHF Bridge Grant, a PHF Clinician Scientist Development Grant, a PHF Team Science Grant, a Research Support Grant, or a PHF Seed Grant for the duration of this award.

 

Presbyterian Health Foundation (PHF) Clinician Scientist Development Grant Program – Request For Applications

• Cycle I PHF Clinician Scientist Development Grant Program Deadline: March 10, 2023

The primary objective of the PHF Clinician Scientist Development Grant Program is to provide funding to a new or early stage clinician scientist faculty member. This award is designed to support the applicant’s clinical and/or translational research project and to assist him or her with advancing this research project to a level that will be competitive for funding through a federal career development award mechanism. This program can provide funding for up to two years. The second year of funding, will be based on successful achievement of identified milestones, completion of an application for Year Two funds, and whether funds are available.

The Principal Investigator must be an OUHSC primary faculty member with appointment at OUHSC as an Assistant Professor. New or early stage clinical scientist faculty members with Temporary Faculty appointments (faculty with academic titles such as instructor, lecturer, or titles modified by prefixes such as visiting, adjunct, clinical, or temporary research appointments with suffix “of Research”) must obtain approval from the Vice President for Research before submitting an application for this program. Approval will require a letter from their Department Chairperson indicating a departmental commitment of salary, research space, and time for development of an independent career at OUHSC.  Requests should be sent to ORA4PHF@ouhsc.edu). Applicants must not have had a prior NIH career development award or an independent NIH R01 award; must have an independent clinical and/or translational research project; must have an identified senior, experienced research mentor; and may not have another PHF grant during the duration of this award.

 

Presbyterian Health Foundation (PHF) Team Science Grant Program – Request For Applications

• Cycle I PHF Team Science Grant Program Deadline: March 24, 2023

The primary objective of this PHF Team Science Grant is to foster innovative, collaborative approaches to research projects involving multiple investigators. The proposal must focus on the collaborative relationship, such that the scientific objectives could not be achieved without the efforts of at least two investigators and their respective expertise and/or disciplines. The proposal must consist of two or more investigators, with the majority at OUHSC, who can develop a broadly based, multidisciplinary research program focused on a specific disease entity, biomedical problem area, or clinically relevant problem. The combination and integration of studies may include basic, clinical, community-based and/or translational research endeavors. The proposal should focus on developing collaborative relationships and co-authored papers required for submission of multi-PI grants, program project grants, center grants, or other large collaborative-type grants (PCORI or AHRQ). The funding for this program can be for up to three years with the 2nd and 3rd year of funding, if funds are available, based on successful achievement of identified milestones, quality of specified milestones to be met during the next year of funding, and submission of a team-type grant application by the end of the 2nd year.

Each proposal submitted must consist of two or more investigators with a single investigator identified as the Contact PI/Team Leader.  The Contact PI/Team Leader must be an OUHSC primary faculty member; adjunct faculty members are not eligible. At least half of the investigators on the team must be OUHSC primary faculty members. The other investigators may be from other institutions.

 

Guidelines and Application Forms are attached or can be found at https://research.ouhsc.edu/research-administration/grants/funding-opportunities/phf-funding. If you have any questions, please email VPR@ouhsc.edu.

 

Call for Faculty Mentors - 2023 OK-INBRE Summer Undergraduate Research Program.

The OK-INBRE Summer Undergraduate Research Program exposes promising students to the exciting world of research and aims to prepare and encourage them to pursue careers in biomedical research and health related sciences.  The faculty mentor, graduate students and laboratory technicians work closely with the undergraduate, teaching science as well as methods and techniques while allowing the student to assume responsibility for the project.  At the end of the program, students will write an abstract with the assistance of their mentor and present a scientific poster of their summer research project.  Each mentor's laboratory will receive $2,200 for lab supplies and poster printing.  Faculty at OUHSC, OU Tulsa, OU Norman, OMRF, OSU, OSU-CHS, the University of Tulsa, as well as Oklahoma’s regional universities are strongly encouraged to apply to serve as summer research mentors.  If you are interesting in serving as a faculty mentor next summer, please complete the brief online MENTOR APPLICATION.  The application deadline is January 31, 2023.  For more information on the OK-INBRE SURP, visit the SURP webpage.

 

Office of Technology Commercialization presents the following opportunity for researchers to engage with industry (click here for more information, or email otc@ou.edu or gina-mcmillen@ouhsc.edu).  

• A multinational pharmaceutical company is seeking novel, established, ligandable drug targets for targeted protein degradation, especially proteolysis-targeting chimeras (PROTACs) in oncology.  Priority cancers of interest include biliary tract, pancreatic, non-small cell lung (PD-L1 negative), prostate cancer (castration-resistant) urothelial, acute myeloid leukemia, triple negative breast cancer, ovarian, soft tissue sarcoma and diffuse large B-cell lymphoma.   Submission entails a 1-pg non-confidential summary of technology with optional supplemental information.  (deadline 02/10).
• A multinational pharmaceutical company is looking for novel technologies or methodologies that allow antibody-drug conjugation (ADC).  Of particular interest are novel linker conjugation technologies or improvements to existing methods for mAB conjugation with conventional small molecule drugs that improve serum stability and physiochemical properties compared to conventional conjugation methods.  Submission entails a 1-pg non-confidential summary of technology with optional supplemental information.  (deadline 02/10).

Investigator Initiated Trials Funding Committee (IITFC), Clinical Trials Office-Protocol Support Unit

Description: Grant proposals are being accepted for the 2023 Spring cycle from Stephenson Cancer Center Providers for their investigator-initiated clinical trials (IITs) or translational work for the amount of up to $100,000 for clinical trials, and up to $25,000 for translation research. All applications should be submitted to the Protocol Support Unit at SCC-IIT-Office@ouhsc.edu and should adhere to the Grant template and Submission Checklist provided with this notice. Investigators should request the budget template from the Protocol Support Unit.

Deadline: April 3, 2023 at 5 pm CST

Link to the full announcement or a flier: Please refer to the attached flyer for additional funding criteria and details

 

NIH Notices 

• AHRQ Announces Interest in Research on Climate Change and Healthcare
  (NOT-HS-23-006)
• Guidance on Salary Limitation for Grants and Cooperative Agreements FY 2023
  (NOT-OD-23-056)
• Notice of Guidance for Data Management and Sharing Plans for the National Institute of Alcohol Abuse and Alcoholism (NIAAA)
  (NOT-AA-23-001)
• Notice of NIAAA Data-Sharing Information for Human Subjects Grants Research Funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) [5th Revision]
  (NOT-AA-23-002)
• Notice of Pre-Application Webinar for RFA-DK-22-012 NIDDK Investigator Award to Support Mentoring of Early Career Researchers from Diverse Backgrounds (K26 - Independent Clinical Trial Not Allowed)
  (NOT-DK-23-008)
• Notice of NIBIB Specific Interests and Guidance in RFA-NS-23-006 HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed)
  (NOT-EB-22-012)
• Notice of Modification to Require All NINDS-Funded TBI Human Subjects Research Data to Submit to the Federal Interagency Traumatic Brain Injury Research (FITBIR) Informatics System
  (NOT-NS-23-046)
• Technical Assistance Webinar for PAR-23-066: Research on Community Level Interventions for Firearm and Related Violence Injury and Mortality Prevention (CLIF-VP)
  (NOT-OD-23-059)
• Notice of Information to Expire the PAR-21-311, Global Brain and Nervous System Disorders Research Across the Lifespan (R01 Clinical Trials Optional)
  (NOT-TW-23-001)
• Notice of Information to Expire PAR-21-319, Global Brain and Nervous System Disorders Research Across the Lifespan (R21 Clinical Trials Optional)
  (NOT-TW-23-002)
• Request for Information (RFI): Cancer Therapeutic Clinical Trials in Low- and Middle-Income Countries
  (NOT-CA-23-015)
• Notice to Extend the Expiration Date of PAR-20-156 "Translational Bioinformatics Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease (R01 Clinical Trial Optional)"
  (NOT-AG-22-051)
• Notice of Early Expiration and Reissue of RFA-DA-22-038, "Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional)"
  (NOT-DA-23-015)
• Notice of Change in Application Due Date for RFA-EB-21-001
  (NOT-EB-22-016)
• Notice of Change to Eligibility information for RFA-NS-23-003 "HEAL Initiative: Interdisciplinary Team Science to Uncover the Mechanisms of Pain Relief by Medical Devices (RM1 Clinical Trial Optional)"
  (NOT-NS-23-057)
• Notice of Change to RFA-PM-23-001, Enhancing the Use of the All of Us Research Programs Data (R21 Clinical Trial Not Allowed);
  (NOT-PM-23-004)
• Notice of Change to RFA-PM-23-002, Small Grants to Enhance the Use of the All of Us Research Programs Data (R03 Clinical Trial Not Allowed)
  (NOT-PM-23-005)
• Notice of Clarification to RFA-TR-22-030 "Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trial Not Allowed)"
  (NOT-TR-23-004)
• Notice of Intent to Publish a Funding Opportunity Announcement for Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
  (NOT-DA-23-014)
• Notice of Request for Proposals (RFP), Solicitation 75N91023R00024: PREVENT Cancer Preclinical Drug Development Program
  (NOT-CA-23-034)
• Notice of Special Interest (NOSI): Adaptive Biomaterials for Cancer Biology
  (NOT-CA-23-030)
• Notice of Special Interest (NOSI): Administrative Supplement to Support Global Cancer Stigma Research
  (NOT-CA-23-036)
• Notice of Special Interest (NOSI): Targeting the Endocannabinoid System for Brain Health and Acute and Chronic Diseases
  (NOT-DA-22-048)
• Notice of Special Interest (NOSI): Administrative Supplements to Support Programs for Inclusion and Diversity Among Individuals Engaged in Health-Related Research (PRIDE) Small Research Projects (SRPs)
  (NOT-HL-22-039)
   

 

NIH Funding Opportunities

• Archiving and Documenting Child Health and Human Development Data Sets (R03 Clinical Trial Not Allowed)
  (PAR-22-261)
  Application Receipt Date(s): Multiple dates, see announcement.
• Formative and Pilot Intervention Research to Optimize HIV Prevention and Care Continuum Outcomes (R34 Clinical Trial Optional)
  (PAR-23-060)
  Application Receipt Date(s): January 09, 2026
• Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)
  (PAR-23-061)
  Application Receipt Date(s): January 09, 2026
• Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional)
  (PAR-23-062)
  Application Receipt Date(s): January 09, 2026
• NIDA Program Project Grant Applications (P01 Clinical Trial Optional)
  (PAR-23-064)
  Application Receipt Date(s): January 07, 2026
• NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Clinical Trial Required)
  (PAR-23-070)
  Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is February 12, 2023.
• NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Independent Clinical Trial Not Allowed)
  (PAR-23-071)
  Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is, February 12, 2023
• Mentored Career Development Program for Early Stage Investigators Using Nonhuman Primate Research Models (K01 Independent Clinical Trial Not Allowed)
  (PAR-23-073)
  Application Receipt Date(s): January 07, 2026
• In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability (R01 Clinical Trial Not Allowed)
  (PAR-23-074)
  Application Receipt Date(s): Multiple dates, see announcement.
• NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional)
  (PAR-23-076)
  Application Receipt Date(s): Multiple dates, see announcement.
• Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (U01 Clinical Trial Optional)
  (PAR-23-082)
  Application Receipt Date(s): February 21, 2025
• Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required)
  (PAR-23-084)
  Application Receipt Date(s): Multiple dates, see announcement.
• Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)
  (PAR-23-087)
  Application Receipt Date(s): Multiple dates, see announcement.
• Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional)
  (PAR-23-101)
  Application Receipt Date(s): Multiple dates, see announcement.
• Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)
  (PAR-23-102)
  Application Receipt Date(s): Multiple dates, see announcement.
• Implementing and Sustaining Evidence-Based Mental Health Practices in Low-Resource Settings to Achieve Equity in Outcomes (R34 Clinical Trial Required )
  (PAR-23-103)
  Application Receipt Date(s): Multiple dates, see announcement.
• Alzheimer's Disease Research Centers (P30 Clinical Trial Not Allowed)
  (RFA-AG-24-001)
  Application Receipt Date(s): September 26, 2025
• Renewal of the Interventions Testing Program (U01 Clinical Trial Not Allowed)
  (RFA-AG-24-002)
  Application Receipt Date(s): June 19, 2023
• Interventions Testing Program (ITP) Data Coordinating Center (U24 Clinical Trial Not Allowed)
  (RFA-AG-24-003)
  Application Receipt Date(s): June 19, 2023
• Planning for the TMD Collaborative for IMproving PAtient-Centered Translational Research (TMD IMPACT) (R34 Clinical Trial Not Allowed)
  (RFA-DE-23-014)
  Application Receipt Date(s): April 14, 2023
• Accelerating Data and Metadata Standards in the Environmental Health Sciences (R24 Clinical Trial Not Allowed)
  (RFA-ES-23-002)
  Application Receipt Date(s): May 10, 2023
• Pediatric Heart Network Clinical Research Centers (UM1 Clinical Trial Optional)
  (RFA-HL-24-001)
  Application Receipt Date(s): May 12, 2023
• Limited Competition: Pediatric Heart Network for the Data Coordinating Center (U24 Clinical Trial Not Allowed)
  (RFA-HL-24-002)
  Application Receipt Date(s): May 12, 2023
• Programs for Inclusion and Diversity Among Individuals Engaged in Health-Related Research (PRIDE) Coordination Center (U24 Clinical Trial Not Allowed)
  (RFA-HL-24-003)
  Application Receipt Date(s): March 10, 2023
• Programs for Inclusion and Diversity Among Individuals Engaged in Health-Related Research (PRIDE) (R25 Clinical Trial Not Allowed)
  (RFA-HL-24-004)
  Application Receipt Date(s): March 10, 2023
• Using Just-in-Time Adaptive Interventions to Optimize Established Adolescent Mental Health Treatments (R61/R33 Clinical Trial Required)
  (RFA-MH-23-170)
  Application Receipt Date(s): February 22, 2023
• Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
  (RFA-NS-23-012)
  Application Receipt Date(s): March 23, 2023
• Animal and Biological Material Resource Centers (P40) (Clinical Trials Not-Allowed)
  (RFA-OD-23-001)
  Application Receipt Date(s): Multiple dates, see announcement.

 

Other Funding Opportunities

HRSA Nurse Anesthetist Traineeship (NAT) Program

Description: The purpose of the Nurse Anesthetist Traineeship (NAT) program is to increase the supply and distribution of Certified Registered Nurse Anesthetists (CRNAs) who are well prepared and well positioned to practice independently and collaboratively within interprofessional teams and to deliver evidence-based, high quality, and safe anesthesia and pain management services. The program aims to expand access to anesthesia services, especially to rural, urban, and tribal underserved communities nationwide. Eligible grant award recipients are accredited institutions that educate registered nurses to become nurse anesthetists; recipient institutions, in turn, disburse funds to students in the form of traineeship support.

Applications Due: February 10, 2023

Link to Full Announcement: https://www.hrsa.gov/grants/find-funding/HRSA-23-002

 

Cystic Fibrosis Foundation Multiple Principal Investigator Clinical Award

Description: The Multiple Principal Investigator (MPI) Clinical Award provides support for multi-investigator-initiated clinical research projects that have the potential to make an important contribution to the CF Foundation’s mission. Research projects may be designed to address a range of research areas, from clinical pilot and feasibility work to clinical (observational/interventional), translational or epidemiologic study approaches. Each investigator is expected to be a significant contributor to the project and share the responsibility and authority for leading and directing the project. Collaborations that bring new investigators and technologies into the CF research community will be given highest priority. Please note that applicants must speak with program staff prior to submission of an LOI. For questions, please contact Dara Riva (driva@cff.org). 

Letter of Intent Due: March 22, 2023

Link to Full Announcement: https://www.cff.org/researchers/multiple-principal-investigator-clinical-award

 

Cystic Fibrosis Foundation Health Equity Team Science Award

Description: The Health Equity Team Science Award RFA will help address key research questions related to health disparities and to improve health equity within the CF Community. The RFA aims to fund cross-disciplinary teams that may propose up to three related research projects (each led by a separate principal investigator) that share a well-defined theme and overall objective. We are holding a webinar on February 28, 2023 from 1-2pm ET to review RFA content and the submission process, and will allow time for Q&A. Please note that applicants must speak with program staff prior to submission of an application. For questions, please contact Dara Riva (driva@cff.org).  

Letter of Intent Due: March 29, 2023

Link to Full Announcement: https://www.cff.org/researchers/health-equity-team-science-award

 

Cystic Fibrosis Foundation Idea Development Award

Description: The Spring 2023 Idea Development Award (IDA) is intended to support work that leads to sufficient project development to enable an application for future research funding from the Cystic Fibrosis Foundation or the National Institutes of Health. For more information, visit the IDA webpage.  For questions, please contact Dara Riva (driva@cff.org).

Applications Due: February 2, 2023

Link to Full Announcement: https://www.cff.org/researchers/idea-development-award

 

HRSA Nursing Anesthetist Traineeship (NAT) Program 

Description: The Health Resources and Services Administration (HRSA) released a new Notice of Funding Opportunity (NOFO) to expand access to anesthesia services, especially to rural, urban, and tribal underserved communities nationwide. The Nurse Anesthetist Traineeship (NAT) Program aims to increase the supply and distribution of new certified registered nurse anesthetists who deliver evidence-based, high quality, and safe anesthesia and pain management services. HRSA will award approximately $2.2 million per year to up to 80 grantees over a period of four years.

Applications Due: February 10, 2023

Link to Full Announcement: https://www.hrsa.gov/grants/find-funding/HRSA-23-002?utm_campaign=Funding+Opportunity%3A+Nurse+Anesthetist+Traineeship+%28NAT%29&utm_medium=email&utm_source=govdelivery

 

The Leona M. and Harry B. Helmsley Charitable Trust

Description: Helmsley T1D Program seeks to fund studies that lead to solutions that improve management of exercise with T1D in the real world. The goal of the projects should be learning from the T1-DEXI data to provide people with T1D and healthcare providers practical management solutions for T1D and exercise and to improve clinical guidelines in a way that can be applied in the real world. All potential projects are expected to include a study component involving people with T1D.

Concept Notes Due: April 30, 2023

Full Grant Proposals Due (selected applicants): July 31, 2023

Link to Full Announcement: https://helmsleytrust.org/request_for_proposal/improving-exercise-with-type-1-diabetes-moving-data-towards-solutions/

 

The Leona M. and Harry B. Helmsley Charitable Trust’s (Helmsley) Type 1 Diabetes (T1D) Program

Description: The Leona M. and Harry B. Helmsley Charitable Trust’s (Helmsley) Type 1 Diabetes (T1D) Program is launching a Request for Proposals (RFP) to support the development of novel, real-world solutions to help people with T1D exercise safely and to improve their quality of life. Researchers and clinicians are expected to partner with statistical teams to analyze the real-world data that was collected under Helmsley’s T1D Exercise Initiative (T1-DEXI), build collaborations with other necessary third parties, and to test their novel solutions in studies with people with T1D. The overarching purpose of this initiative is to move real-world data towards real-world solutions.

 Concept Notes due: April 30, 2023

Link to Full Announcement: https://helmsleytrust.org/request_for_proposal/improving-exercise-with-type-1-diabetes-moving-data-towards-solutions/